Both authors contributed equally as senior authors.
Introduction
Medical images possess valuable information which can be harnessed through computer assisted interpretation. This technique, termed radiomics, is a rapidly-emerging discipline with the goal of extracting quantitative data from medical images to be used as clinical decision support tools [1] [2] [3] . In the context of oncology, information obtained from standard imaging modalities [computed tomography scan (CT), magnetic resonance imaging (MRI), and Positron emission tomography scan (PET)], usually refers to simple traits such as gross shape, contrast enhancement, and size. However, imaging information is much richer, and the goal of radiomics is to extract high throughput quantitative features, covering the fields of texture, advanced shape modeling, and heterogeneity, to name a few. The increasing resolution quality has led to three-dimensional (3D) image acquisitions containing millions of voxels available for analysis, making the development of radiomics a natural progression, as more data necessitated increased computing capabilities to harness more information.
Radiomics has immense potential to improve knowledge in tumor biology and guide the management of patients at bedside [4] . Medical image analysis allows tumor monitoring across time, with images being routinely acquired throughout the course of treatment. Thus, imaging biomarkers may be used for and contribute to cancer detection, diagnosis, choice of therapeutic strategy, prognosis inference, prediction of response, and surveillance. Tumors exhibit spatial heterogeneity and temporal variation, recognized as major causes of treatment failure and modulators of intrinsic tumor aggressiveness [5] [6] [7] . Imaging allows assessment of the entire tumor plus surrounding tissue-it is not blind to global heterogeneity-as opposed to invasive needle biopsies that are limited by sampling site. Radiomics could serve as a 'virtual biopsy' that would provide complementary information to, but not replace, conventional biopsies which remain vital in deep genomic analysis.
This review will systematically go through the radiomics pipeline, the significant milestones achieved in oncology, and future perspectives for improvement. The aim is to increase the awareness and interest of the oncology community to radiomics, demystify the field for non-imaging experts, and engage the community to be involved in its further development and adoption in clinical practice. We will demonstrate the potential of radiomics to advance precision medicine.
Radiomics pipeline
The process of radiomics consists of discrete steps: image acquisition and segmentation, feature extraction, statistical learning and 3D rendering (Figure 1 ).
Image acquisition and segmentation
Radiomics may be applied to different/multiple modalities, and selecting the one(s) to investigate depends on several factors. Radiomics quantitatively explores the distribution of signal intensities within a region or volume of interest (ROI/VOI). The spatial resolution of images varies, being around 1 mm for CT and MRI and 4 mm for PET. ROIs that are too small (e.g. sub-centimeter nodules) may not provide sufficient voxel information for analysis, whereas ROIs that are too large may be impacted by tumor heterogeneity (e.g. large tumors often present hypoxia in their centers). Standardization and calibration of non-ionizing procedures (Ultrasound, MRI) are intrinsically more complex than techniques based on photon detection (PET or CT) [8] . The minimal concentration of a molecule that is detectable on PET is 10 À12 moles compared with 10 À3 moles for MRI, meaning that the former might be 10 9 more sensitive for in vivo molecular imaging. Patient motion and respiration during acquisition affects the quality of reconstructed images; a CT is usually acquired in a few seconds whereas functional (MRI) or molecular (PET) imaging lasts several minutes. Data might be extracted from retrospective standard-of-care images, leading to large pool of patients. However, acquisition parameters vary considerably, which can introduce signal variations not due to biologic effects [8] [9] [10] . As with other high throughput technologies such as genomics, the aggregation of multiple datasets in radiomics can lead to substantial unwanted effects on the data. In determining the inclusion criteria for studies, an option is to have a large cohort in order to be less sensitive to variations due to acquisition/reconstruction parameters, or have a small cohort with homogenous data.
Crucial in the process is correct delineation of ROIs to be analyzed. Segmentations must be reproducible and reliable. Automatic methods are preferable for precision and efficiency. It has been proven that inter-and intra-observer variabilities are lower in automatic versus semi-automatic versus manual delineation [10] [11] [12] [13] . However, semi-automatic delineation is usually mandatory, since automated methods are feasible only if there are strong signal differences between the lesion and the background. This is observed in PET and CT of pulmonary tumors, and possibly in certain MRI sequences. Commonly, such as in tumors surrounded by relatively homogenous normal structures, an experienced physician is required to correct contours, entailing computer-aided outline detection followed by manual correction.
Currently, there are several open source platforms equipped with automatic and semi-automatic contouring functions, such as 3DSlicer (Growcut algorithm) [14] , which have active online support, and are continuously updated. Generated contours should be stored in an easily utilizable format for analysis across various platforms. Commonly used is DICOM-RTSTRUCT, The radiomics pipeline, showing the major steps: image acquisition and segmentation, feature extraction, three-dimensional (3D) rendering and statistical learning. Important to note is that radiomics data is meant to be integrated and analyzed with clinical, pathologic, and -omics data to improve precision medicine.
which enables data sharing within and outside of the radiotherapy workflow, containing information on the images and ROIs [15] . Other formats such as analyze [16] and NIfTI are also used [17] .
Feature extraction
Preprocessing. Raw imaging data need pre-processing to discriminate the signal from the noise. One optional step is filtering the signal within the ROI, which defines the frequencies to be utilized for subsequent analysis [18] . The choice of filter is guided by the nature of the imaging modality and tumor tissue. Another is the discretization or resampling [19, 20] of signal intensities that partitions continuous voxel values to finite/nominal intervals called bins. Techniques involve either absolute (using a fixed bin size) or relative (using a fixed number of bins whose size depends on the minimum and maximum values within the tumor) discretization. The choice of method is crucial as extracted features vary accordingly [21, 22] . Several studies [19, 20, 23] have shown that absolute discretization results to features with better repeatability and lower sensitivity to changes, with the added advantage of not being volume dependent.
Radiomics features. Features may be classified into several categories. There are quantitatively extracted descriptors of size, shape, and other radiologic terminologies which characterize the tumor surface. First-order statistics are used to study the distribution of voxel values without considering spatial relationships [24] ; second-order statistics characterize spatial relationships between voxels, initially described by Haralick [25] such as the cooccurrence matrix (GLCM), gray-level run length matrix (GLRLM) [26] , gray-level size zone matrix (GLZLM) [27] , and the neighborhood gray-level different matrix (NGLDM) [28] . Filter grids such as Gabor and Fourier may be used both in the pre-processing step and for extracting spatial or spatio-temporal features [29, 30] . A limitation is that some extracted values are dependent on the ROIs contoured. The extracted features can be global (one value for the whole ROI), or local (a value per image patch) when inhomogeneous patterns are present in the image, where dimensionality significantly increases if simple concatenation of local descriptors is carried out. For this, more advanced frameworks explore compact statistical representations based on coding structures/dictionaries. When visual vocabularies and visual word weights are learned jointly, performance can be improved, as shown in classification of breast tissue density in mammograms, lung tissue in high-resolution CT, and brain tissue in MRI [31] . A more detailed review on texture analysis methods focusing on microscopy images of cells or tissues can be found in [32] .
The stability and the accuracy of features should be confirmed through the use of test-retest datasets; a good practice policy is to eliminate features that prove to be unreliable in the test-retest. To this end, several datasets are publicly available. Of note is the RIDER [33] dataset, which allows validation of results in the same set of patients with two scans taken 15 min apart.
Statistical learning
The impact of the high number of radiomics variables. The current radiomics pipeline typically incorporates around 50-5000 quantitative features (p), and these are still expected to increase. Meanwhile, the number of patients (n) in studies remains small, leading to a situation where p ) n, or the 'curse-of-dimensionality' [34] ; resulting in a high probability of false positive results [35] . Adjustments for multiple comparisons (Bonferroni correction [36] ) and controlling the false discovery rate (BenjaminiHochberg [37] ) are commonly utilized methods to address this. Another issue is overfitting, which can be reduced by crossvalidation with independent training and validation datasets [34] . Several techniques of dimensionality reduction can be used to reduce the number of variables for analysis by exploiting statistical correlations and data redundancy [38] . Unsupervised techniques map the data through a linear (e.g. prinicipal and independent component analyses) or non-linear (e.g. ISOMAP, locally linear embedding) transformation in a lower-dimensional space, such that information loss is minimized, whereas supervised techniques select a subset of the original variables such that prediction accuracy is maximized. Feature selection can be carried out independently, before classification or regression, or be combined into a single mathematical problem (e.g. Lasso, ElasticNet) [39] . Attention has to be given in the case of supervised learning and small datasets to not overfit the data; feature selection should be carried out externally to the cross-validation procedure to correctly estimate the empirical error.
Promising machine learning approaches for prediction and classification tasks. Machine learning approaches [40] such as decision trees and random forests [41] [42] [43] [44] [45] [46] , support vector machines [39, 47, 48] and more recently deep neural networks [49] appear to be promising in the domain of medical image computing. The recent increase of available annotated imaging data in public portals expedited the use of these techniques. In particular, deep convolutional neural networks (CNNs) have been shown to excel at learning a hierarchy of increasingly complex features directly from raw data, alleviating the explicit extraction of low-order, pre-defined features. In such frameworks, feature extraction and selection are carried out jointly with classification within the optimization of the same deep architecture, thus performance can be tuned in a systematic fashion. Common CNN schemes train patch-level classifiers [50] that automatically locate discriminative regions and then aggregate local predictions. The learning process is usually facilitated by pre-training using standardized data followed by supervised training for fine-tuning.
Thus far, CNNs have been shown to excel in the detection and classification of pulmonary nodules in large series of lung CTs from the Lung Image Database Consortium (LIDC-IDRI) [41, 43, 51] . A comparison in mortality prediction from chest CTs [52] between (i) a unified deep learning framework (features and classifier are automatically learned in a single optimization process) and (ii) a standard multi-stage framework (pre-defined radiomics features are introduced into a classifier), showed increased accuracy of the deep learning framework by 2.5%-12.5%. Similar concepts have been applied to mammograms for breast cancer screening [53, 54] .
Three-dimensional rendering
The visualization of the entire tumor, commonly carried out in diagnostic radiology, is possible through 3D rendering [55] . Radiomics takes this a step further through visualization and assessment of tumor heterogeneity which provides invaluable information in clinical oncology and in cancer research. For instance, this can direct which intra-tumoral region is best to biopsy for adequate samples. In radiotherapy dose painting, rendering is instrumental in visualizing treatment-resistant regions, facilitating dose escalation and consequently decreasing normal tissue toxicity [56] . Theragnostic imaging [57] , the use of molecular/functional imaging to prescribe radiation distribution, will benefit from radiomics features reflecting phenotypes associated with poor radio-responsiveness [58] .
Significant milestones of radiomics in oncology
Radiomics is substantial in oncology, not surprising given the increased availability of and information in patient imaging data. Oncologic imaging is a substantial part of a radiologist's daily workload. More than 128 million imaging examinations were realized in the United States in 2015, greater than 60% of which were CTs ( Figure 2B) ; and an increase of >36% in use of advanced imaging was seen from 2005 to 2015 [59] , reiterating the vast amount of available data. This section aims to depict the impact of radiomics in each stage of cancer care, with tables outlining key details.
Advancements in the understanding of tumor biology
Tumor heterogeneity. The extensive genetic and molecular landscape within tumors-tumor heterogeneity-is known to be specific to the malignant process. Intra-tumoral heterogeneity is dynamic and is modified by therapeutic effects. Heterogeneity may portend treatment resistance and poor outcomes due to the emergence of resistant subclonal populations [60] . Through quantitative serial analysis of imaging, both temporal and spatial heterogeneities may be analyzed. In particular, texture analysis is emerging as an effective method to quantify heterogeneity. Table 1 displays some representative work. To illustrate, in CTs of lung adenocarcinomas, entropies of the tumor core and boundary regions were computed separately, with results showing that a higher ratio between the two are associated with poorer outcome [61] . Thus, this imaging phenotype may reflect distinct traits such as necrosis in the core and proliferation in the periphery. In PET, texture analysis showed that healthy lung tissues are more homogenous than malignancies, and texture features differentiated tumor histologies [20] . Similar studies on texture heterogeneity, with or without other feature classes, depict quantitative imaging traits mirroring genomic and molecular phenotypes [62] [63] [64] [65] [66] [67] [68] [69] .
Modeling of key oncogenic processes. Several biological processes are known to be necessary components of oncogenesis [70, 71] . Various molecular biology techniques have been developed to better appraise biological and genetic causes of these, and the emergence of quantitative imaging analysis is a promising tool to complement and enhance existing techniques.
A study in lung cancer used an angiogenesis-related marker injected in specimens, and linear correlations were shown between CT texture heterogeneity features and percentage of the tumor stained for the marker [72] . In glioblastomas, the 'contrast enhancement imaging phenotype' was significantly associated with tumor angiogenesis [64] . In breast cancers, certain computer extracted imaging phenotypes of MRIs have been shown to differentiate subtypes [62] .
In lung cancers, multi-categorical quantitative imaging features were shown to reflect tumor hypoxia [63, 66] . In the preclinical setting, causal relationship between genetic changes and imaging features was demonstrated by pre-imaging administration of doxycycline which induces hypoxic changes [73] . Clinically, these results may be helpful in identifying tumor resistance and the need for intensified regimens. Further, radiomics phenotypes have been shown to correlate with mRNA and protein expression in breast MRIs [74] , alluding to the underlying mechanisms of tumor invasion. In glioblastomas, peritumoral fluid attenuation inversion recovery MRI signal abnormalities were found to reflect genes and microRNAs accounting for cellular migration and invasion [75] . In addition, lymphocyte infiltration has been reflected in imaging features of HER2þ breast cancers [76] .
Radiomics features also appear to model tumor proliferation. A landmark study in liver cancer demonstrated that the combination of 28 traits could reconstruct as much as 78% of transcriptome variation, and were specifically associated with genes involving cell proliferation [77] . In breast cancers, analysis of TCGA-TCIA data revealed clear associations between radiomics phenotypes and proliferation at the protein and gene expression levels. Imaging phenotypes of increased tumor size were also associated with P-cadherin expression, shown to correlate with increased proliferation [74] .
Better implementation of precision medicine
Precision medicine is an approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle; integrating information from multiple sources with the end goal of personalized management [78] . In this section, some key radiomics applications are described.
Diagnosis. One of the biggest challenges in oncology is the development of accurate, cost-effective screening procedures. In the National Lung Cancer Screening Trial (NLST), low-dose CTs interpreted by radiologists have been shown to be beneficial in mortality reduction in a cohort of 53 000 patients [79] . These however exhibit high false-positive rates (>90%); wherein radiomics could be effective in improving specificity. Using NLST data, patients with screening-detected lung cancer were matched with subjects with benign nodules. Accuracies of 80% and 79% were found for predicting nodules that will become cancerous at 1 and 2 years, respectively [42] . Using LIDC-IDRI patients with a total of 42 340 lesions (through data augmentation), deep convolutional sequencers detected malignant nodules with diagnostic accuracy, sensitivity, and specificity >75% [41] . Two studies [43, 80] with 914 and 1375 lesions, respectively, published promising results with predictive performances ranging from 60% to 80%. Notably, multi-scale CNNs attained 86.84% accuracy on classification with automatic nodule detection and segmentation [43] . Other publications in lung carcinomas reveal similar findings [46, 81, 82] . Table 2 presents representative publications concerning diagnosis.
Staging and prognosis. Accurate staging determines the aggressiveness of therapeutic strategy and spells the difference between curative and palliative treatments, requiring constant advancements in imaging techniques to improve decision-making. In colorectal carcinomas, for which liver metastases are frequent, radiomics features extracted from unenhanced hepatic CT scans showed texture abnormalities suggestive of metastases in apparently disease-free areas [83] . This could streamline the staging process and minimize treatment delays with the information steering the clinician toward doing confirmatory examinations for patients at risk. Plus, early detection of metastases may increase chances of complete tumor eradication. In prognostication, increased shape complexity in lung adenocarcinoma [61] was associated with poorer clinical outcomes. Morphologically similar tumors by visual inspection turned out to have large differences in quantitative parameters, denoting that radiomics can supplement radiologists' interpretations. Another study [84] demonstrated that radiomics features are prognostic for both distant metastasis and survival, and a radiomics signature significantly improves prognostication when added to clinical data. Similar studies were published in colorectal cancers [85, 86] . In a large cohort involving multiple datasets with varying tumor types [4] , differences in imaging phenotypes showed clinical significance and impact on prognosis. These results were reiterated in a dataset of almost 900 patients [87] and externally validated in oropharyngeal cancers [88] . Table 3 shows recent radiomics publications on tumor staging and prognosis.
Prediction of treatment response. Radiomics features could be used to predict which patients would respond to a treatment regimen. Table 4 summarizes notable publications. In glioblastomas, a robust association between radio-phenotypes and gene expression has been shown, including a link with epidermal growth factor receptor (EGFR) overexpression [64, 89] . Radiomics features have been shown to stratify treatment outcomes from angiogenic therapy in recurrent glioblastomas [90] . EGFR mutation [91] and response to Gefinitib [92] were also reflected in a combination of features in lung cancers. With the rapid rise in targeted therapy, it is worthwhile to continue discovering radiogenomic associations that may influence management. An imaging surrogate to could aid patient selection and avoid unwarranted expense and toxicities for nonresponders.
In the neoadjuvant chemotherapy setting, a multi-parametric model in breast MRIs identified non-responders with 84% sensitivity [93] , with the goal of developing a computer-assisted prediction solution, which may be more cost-effective than molecular assessments. In rectal carcinomas, a combination of radiomics features was seen to be predictive of pathologic response to neoadjuvant treatment [49] . Studies in other cancer localizations [94] [95] [96] [97] have shown the possibility of assessing treatment response using imaging markers.
In the advent of immunotherapy, there have been been patients who experience pseudoprogression (PSPD) [98] , which has been shown to be due to lymphocyte infiltration in and around the tumor [99] . A study demonstrated that a radiomics signature from CTs could reflect tumors with increased lymphocytes and discriminate PSPD from true progression [100] , possibly aiding decision-making for equivocal cases.
Disease monitoring and surveillance. Inflammation leads to posttreatment reactions that might complicate response evaluation by imaging. In this context, functional imaging helps differentiate scar tissue from viable tumor, but equivocal cases remain. Radiomics can further enhance evaluation. For instance, texture features from CT images of lung cancer treated with stereotactic ablative body radiotherapy (SABR) showed that the ground glass appearance (an area of hazy increased lung opacity through which vessels and bronchial structures may still be seen [101] ), following SABR predicts recurrence versus radiation-induced lung injury, which has a similar radiologic picture [102] . This is particularly useful because lung cancer typically progresses quickly; hence the decision for salvage therapy is most valuable if made early, likely providing more treatment options compared with late-detected disease. In addition, a pilot study on renal cell cancers has demonstrated the possibility of capturing sub-visual treatment-related imaging changes [103] . CT, computed tomography scan; MRI, magnetic resonance imaging, CE, contrast-enhanced; TCGA-TCIA, The Cancer Genome Atlas-The Cancer Imaging Archive; NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; CI, concordance index; AUC, area under the curve; LASSO, least absolute shrinkage and selection operator; PFS, progression-free survival; OS, overall survival; CEIPs, computer-extracted image phenotypes. There is convincing evidence that radiomics could be an invaluable tool in revolutionizing oncology. Significant progress has been made, but further improvements are imperative to achieve routine utilization from bench to bedside.
Standardization and the perspective relative to molecular biomarkers
Radiomics literature is constantly growing, and we predict that it will follow the curve of the molecular biomarkers as interests and funding increase (Figure 2A ). At present, however, the existing level of evidence is insufficient (Figure 3 ). There are notable differences in terms of sample size, methodology, performance metrics, and clinical utility; reiterating that improvements are essential.
As investigators have learned from discovery of biomarkers [104, 105] , there are pitfalls to be avoided. In the same way as the REporting recommendations for tumour MARKer prognostic studies (REMARK) [106] or the Minimum information about a microarray experiment (MIAME) [107] guidelines, recommendations specific to radiomics are necessary. In reporting, key elements should be sufficiently detailed and made available to allow comparisons and validation: (i) raw imaging data including acquisition parameters, (ii) ROIs, (iii) radiomics features and the extraction software, methods, formulae used, and (iv) statistical learning methods. Meriting attention is the non-standardized names of extracted features, such that two publications might discuss a feature with the same formula/definition but call these differently.
The recently published roadmap for imaging biomarkers [108] is a notable advancement, showcasing key recommendations for clinical translation of radiomics. Also admirable are large initiatives aiming to develop automatic segmentation solutions such as the Google-National Health Service partnership DeepMind Health project [109] . Another is the Grand Challenges in Biomedical Image Analysis [110], with goals of developing algorithms for specific problems such as the Lung Nodule Analysis (LUNA) Challenge [111] , a large-scale automatic nodule detection with 888 patients and The Digital Mammography (DREAM) Challenge [112] aiming to improve predictive accuracy of digital mammography with over 640 000 images. To ensure robustness and dissemination of radiomics-based predictive tools, standardization of imaging protocols and feature calculations is ideal, but seldom attainable [10, 113] . Imaging carried out at different centers leads to bias [10, 114] . In fact, significant variation of radiomics features was observed across different CT scans through a phantom experiment [113] . The use of credentialing scanners, careful study design, noise reduction, and statistical analyses adjusted to account for unwanted effects are possible solutions. Table 5 highlights the current challenges and corresponding recommendations in radiomics. Researchers should be encouraged to submit data to a centralized online radiomics repository akin to the Gene Expression Omnibus [116] for microarrays. A standardized non-software dependent format of storing and annotating data will facilitate multi-platform utilization. These will not only be useful before starting research projects, but also during and after; ensuring the integrity and availability of information. These must allow incorporation of image features, annotations, medical information, and genetic data in order to create prognostic and predictive models correlating imaging with genetic phenotypes and clinical outcomes. It is critical that the fidelity of the data is maintained and access is regulated, for which competent system administrators are mandatory. These are big steps, but we believe they are essential for the advancement of the discipline. Forming a multi-national consortium may be a prudent solution, some of whose functions would be to (i) draft guidelines on data collection, anonymization, and sharing, (ii) standardize reporting of radiomics studies.
Actual data access
Improving multi-disciplinary network and dissemination of radiomics , whose goals include enhancing data sharing and facilitating patient recruitment in clinical trials. More initiatives are necessary, with multi-disciplinary working groups that include oncologists, radiologists, medical physicists, applied mathematicians, and computer scientists, to improve the field and educate people on its use such that it can become a reliable part of a decision support system in oncology. Radiomics has been gaining ground in terms of exposure and interest in recent scientific congresses, with the number of publications per year almost doubling in the last three and almost tripling in the last five years (197 in 2015, an increase of 77% since 2013 and 186% since 2011) (Figure 2A ). This is translated in increased exposure of radiomics in current radiology meetings (e.g. RSNA) and in major oncology meetings (e.g. ASCO, ESMO, AACR, ASTRO). This is a formidable start but efforts need to be increased.
Discussion Conclusion
Imaging biomarkers constructed from quantitative image analysis have great potential to advance precision medicine and to enhance cancer biology knowledge. As radiomics cements its position in translational cancer research to attain utilization at bedside, we anticipate radiomics data being integrated and analyzed with genomics, proteomics and other -omics; providing information invaluable in personalized medicine. Radiomics will certainly progress further with the advent of more imaging data, better algorithms, and availability of other data types such as coherent datasets integrating imaging, clinical, and genomic information.
